ImmunityBio (IBRX) Stock Forecast, Price Target & Predictions
IBRX Stock Forecast
ImmunityBio stock forecast is as follows: an average price target of $8.00 (represents a 53.85% upside from IBRX’s last price of $5.20) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IBRX Price Target
The average price target for ImmunityBio (IBRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 53.85% upside from IBRX's last price of $5.20.
IBRX Analyst Ratings
According to 2 Wall Street analysts, ImmunityBio's rating consensus is 'Buy'. The analyst rating breakdown for IBRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
ImmunityBio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 03, 2022 | Kelly Shi | Jefferies | $8.00 | $4.13 | 93.94% | 53.85% |
The latest ImmunityBio stock forecast, released on Aug 03, 2022 by Kelly Shi from Jefferies, set a price target of $8.00, which represents a 93.94% increase from the stock price at the time of the forecast ($4.13), and a 53.85% increase from IBRX last price ($5.20).
ImmunityBio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.20 | $5.20 | $5.20 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of ImmunityBio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ImmunityBio's last price of $5.20. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | EF Hutton | - | Buy | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
ImmunityBio's last stock rating was published by EF Hutton on Oct 23, 2024. The company Initialise its IBRX rating from "null" to "Buy".
ImmunityBio Financial Forecast
ImmunityBio Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $139.00K | $360.00K | $73.00K | $118.00K | $35.00K | $14.00K | $390.00K | $66.00K | $339.00K | $139.00K |
| Avg Forecast | $973.40M | $935.97M | $935.97M | $898.53M | $387.24M | $372.35M | $372.35M | $357.46M | $122.94M | $118.22M | $118.22M | $113.49M | $43.46M | $40.11M | $36.36M | $30.50M | $6.16M | $2.92M | $14.71M | $62.50K | $25.00K | $25.00K | $25.00K | $118.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K |
| High Forecast | $973.40M | $935.97M | $935.97M | $898.53M | $387.24M | $372.35M | $372.35M | $357.46M | $122.94M | $118.22M | $118.22M | $113.49M | $43.46M | $40.11M | $36.36M | $30.50M | $6.16M | $3.37M | $14.71M | $62.50K | $25.00K | $25.00K | $25.00K | $118.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K |
| Low Forecast | $973.40M | $935.97M | $935.97M | $898.53M | $387.24M | $372.35M | $372.35M | $357.46M | $122.94M | $118.22M | $118.22M | $113.49M | $43.46M | $40.11M | $36.36M | $30.50M | $6.16M | $2.48M | $14.71M | $62.50K | $25.00K | $25.00K | $25.00K | $118.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.56% | 14.40% | 2.92% | 1.00% | 1.40% | 0.56% | 15.60% | 2.64% | 13.56% | 5.56% |
ImmunityBio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $62.50K, with a low forecast of $62.50K, and a high forecast of $62.50K. IBRX's average Quarter revenue forecast represents a -55.04% decrease compared to the company's last Quarter revenue of $139.00K (Dec 23).
ImmunityBio EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-79.94M | $-109.79M | $-82.93M | $-90.51M | $-78.70M | $-91.84M | $-83.17M | $-80.33M | $-80.72M | $-73.47M |
| Avg Forecast | $-973.40M | $-935.97M | $-935.97M | $-898.53M | $-387.24M | $-372.35M | $-372.35M | $-357.46M | $-122.94M | $-118.22M | $-118.22M | $-113.49M | $-43.46M | $-40.11M | $-36.36M | $-30.50M | $-6.16M | $-2.92M | $-14.71M | $-62.50K | $-25.00K | $-25.00K | $-25.00K | $-118.00K | $-25.00K | $-73.84M | $-25.00K | $-25.00K | $-25.00K | $-98.38M |
| High Forecast | $-973.40M | $-935.97M | $-935.97M | $-898.53M | $-387.24M | $-372.35M | $-372.35M | $-357.46M | $-122.94M | $-118.22M | $-118.22M | $-113.49M | $-43.46M | $-40.11M | $-36.36M | $-30.50M | $-6.16M | $-2.48M | $-14.71M | $-62.50K | $-25.00K | $-25.00K | $-25.00K | $-118.00K | $-25.00K | $-59.07M | $-25.00K | $-25.00K | $-25.00K | $-78.70M |
| Low Forecast | $-973.40M | $-935.97M | $-935.97M | $-898.53M | $-387.24M | $-372.35M | $-372.35M | $-357.46M | $-122.94M | $-118.22M | $-118.22M | $-113.49M | $-43.46M | $-40.11M | $-36.36M | $-30.50M | $-6.16M | $-3.37M | $-14.71M | $-62.50K | $-25.00K | $-25.00K | $-25.00K | $-118.00K | $-25.00K | $-88.60M | $-25.00K | $-25.00K | $-25.00K | $-118.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3197.56% | 4391.56% | 3317.12% | 767.04% | 3148.12% | 1.24% | 3326.92% | 3213.12% | 3229.00% | 0.75% |
undefined analysts predict IBRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ImmunityBio's previous annual EBITDA (undefined) of $NaN.
ImmunityBio Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-233.39M | $-151.16M | $-108.33M | $-110.94M | $-94.59M | $-102.83M | $-91.55M | $-87.63M | $-89.39M | $-80.48M |
| Avg Forecast | $410.79M | $399.32M | $403.78M | $366.55M | $123.10M | $122.00M | $126.60M | $116.57M | $-31.46M | $-25.35M | $-19.37M | $-25.28M | $-91.88M | $-84.42M | $-84.84M | $-90.85M | $-114.95M | $-122.30M | $-109.91M | $-133.95M | $-123.65M | $-185.47M | $-151.13M | $-192.34M | $-164.87M | $-84.13M | $-144.26M | $-137.39M | $-82.43M | $-106.61M |
| High Forecast | $410.79M | $399.32M | $403.78M | $366.55M | $123.10M | $122.00M | $126.60M | $116.57M | $-31.46M | $-25.35M | $-19.37M | $-25.28M | $-91.88M | $-84.42M | $-84.84M | $-90.85M | $-114.95M | $-115.50M | $-109.91M | $-133.95M | $-123.65M | $-185.47M | $-151.13M | $-192.34M | $-164.87M | $-67.30M | $-144.26M | $-137.39M | $-82.43M | $-85.28M |
| Low Forecast | $410.79M | $399.32M | $403.78M | $366.55M | $123.10M | $122.00M | $126.60M | $116.57M | $-31.46M | $-25.35M | $-19.37M | $-25.28M | $-91.88M | $-84.42M | $-84.84M | $-90.85M | $-114.95M | $-122.30M | $-109.91M | $-133.95M | $-123.65M | $-185.47M | $-151.13M | $-192.34M | $-164.87M | $-100.96M | $-144.26M | $-137.39M | $-82.43M | $-127.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.89% | 0.82% | 0.72% | 0.58% | 0.57% | 1.22% | 0.63% | 0.64% | 1.08% | 0.75% |
ImmunityBio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IBRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ImmunityBio SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.05M | $32.68M | $26.21M | $19.31M | $16.57M | $40.61M | $27.91M | $29.63M | $32.45M | $45.27M |
| Avg Forecast | $179.13B | $172.24B | $172.24B | $165.35B | $71.26B | $68.52B | $68.52B | $65.78B | $22.62B | $21.75B | $21.75B | $20.88B | $8.00B | $7.38B | $6.69B | $5.61B | $1.13B | $538.28M | $2.71B | $11.50M | $4.60M | $4.60M | $4.60M | $21.72M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M |
| High Forecast | $179.13B | $172.24B | $172.24B | $165.35B | $71.26B | $68.52B | $68.52B | $65.78B | $22.62B | $21.75B | $21.75B | $20.88B | $8.00B | $7.38B | $6.69B | $5.61B | $1.13B | $619.57M | $2.71B | $11.50M | $4.60M | $4.60M | $4.60M | $21.72M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M |
| Low Forecast | $179.13B | $172.24B | $172.24B | $165.35B | $71.26B | $68.52B | $68.52B | $65.78B | $22.62B | $21.75B | $21.75B | $20.88B | $8.00B | $7.38B | $6.69B | $5.61B | $1.13B | $455.75M | $2.71B | $11.50M | $4.60M | $4.60M | $4.60M | $21.72M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M | $4.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.31% | 7.10% | 5.70% | 0.89% | 3.60% | 8.83% | 6.07% | 6.44% | 7.05% | 9.84% |
ImmunityBio's average Quarter SG&A projection for Mar 24 is $11.50M, based on 1 Wall Street analysts, with a range of $11.50M to $11.50M. The forecast indicates a -60.40% fall compared to IBRX last annual SG&A of $29.05M (Dec 23).
ImmunityBio EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.35 | $-0.35 | $-0.27 | $-0.28 | $-0.24 | $-0.26 | $-0.23 | $-0.22 | $-0.23 | $-0.21 |
| Avg Forecast | $0.60 | $0.58 | $0.59 | $0.53 | $0.18 | $0.18 | $0.18 | $0.17 | $-0.05 | $-0.04 | $-0.03 | $-0.04 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.17 | $-0.18 | $-0.16 | $-0.20 | $-0.18 | $-0.27 | $-0.22 | $-0.28 | $-0.24 | $-0.22 | $-0.21 | $-0.20 | $-0.12 | $-0.41 |
| High Forecast | $0.60 | $0.58 | $0.59 | $0.53 | $0.18 | $0.18 | $0.18 | $0.17 | $-0.05 | $-0.04 | $-0.03 | $-0.04 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.17 | $-0.17 | $-0.16 | $-0.20 | $-0.18 | $-0.27 | $-0.22 | $-0.28 | $-0.24 | $-0.22 | $-0.21 | $-0.20 | $-0.12 | $-0.41 |
| Low Forecast | $0.60 | $0.58 | $0.59 | $0.53 | $0.18 | $0.18 | $0.18 | $0.17 | $-0.05 | $-0.04 | $-0.03 | $-0.04 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.17 | $-0.18 | $-0.16 | $-0.20 | $-0.18 | $-0.27 | $-0.22 | $-0.28 | $-0.24 | $-0.22 | $-0.21 | $-0.20 | $-0.12 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.94% | 1.30% | 1.23% | 1.00% | 1.00% | 1.18% | 1.10% | 1.10% | 1.92% | 0.51% |
According to undefined Wall Street analysts, ImmunityBio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IBRX previous annual EPS of $NaN (undefined).
ImmunityBio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| CVAC | CureVac | $2.71 | $29.00 | 970.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| LXRX | Lexicon Pharmaceuticals | $1.21 | $6.00 | 395.87% | Buy |
| VIR | Vir Bio | $9.37 | $26.60 | 183.88% | Buy |
| PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
| IBRX | ImmunityBio | $5.20 | $8.00 | 53.85% | Buy |
| ARDX | Ardelyx | $5.89 | $8.75 | 48.56% | Buy |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
IBRX Forecast FAQ
Is ImmunityBio a good buy?
Yes, according to 2 Wall Street analysts, ImmunityBio (IBRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of IBRX's total ratings.
What is IBRX's price target?
ImmunityBio (IBRX) average price target is $8 with a range of $8 to $8, implying a 53.85% from its last price of $5.2. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ImmunityBio stock go up soon?
According to Wall Street analysts' prediction for IBRX stock, the company can go up by 53.85% (from the last price of $5.2 to the average price target of $8), up by 53.85% based on the highest stock price target, and up by 53.85% based on the lowest stock price target.
Can ImmunityBio stock reach $8?
IBRX's average twelve months analyst stock price target of $8 does not support the claim that ImmunityBio can reach $8 in the near future.
What are ImmunityBio's analysts' financial forecasts?
ImmunityBio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.49B (high $1.49B, low $1.49B), average EBITDA is $-1.489B (high $-1.489B, low $-1.489B), average net income is $488.28M (high $488.28M, low $488.28M), average SG&A $274.09B (high $274.09B, low $274.09B), and average EPS is $0.711 (high $0.711, low $0.711). IBRX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $3.74B (high $3.74B, low $3.74B), average EBITDA is $-3.744B (high $-3.744B, low $-3.744B), average net income is $1.58B (high $1.58B, low $1.58B), average SG&A $688.97B (high $688.97B, low $688.97B), and average EPS is $2.3 (high $2.3, low $2.3).
Did the IBRX's actual financial results beat the analysts' financial forecasts?
Based on ImmunityBio's last annual report (Dec 2023), the company's revenue was $622K, beating the average analysts forecast of $50K by 1144.00%. Apple's EBITDA was $-343M, beating the average prediction of $-50K by 685604.00%. The company's net income was $-583M, beating the average estimation of $-309M by 88.66%. Apple's SG&A was $129.62M, beating the average forecast of $9.2M by 1308.71%. Lastly, the company's EPS was $-1.15, beating the average prediction of $-0.45 by 155.56%. In terms of the last quarterly report (Dec 2023), ImmunityBio's revenue was $139K, beating the average analysts' forecast of $25K by 456.00%. The company's EBITDA was $-79.939M, beating the average prediction of $-25K by 319656.00%. ImmunityBio's net income was $-233M, beating the average estimation of $-124M by 88.75%. The company's SG&A was $29.05M, beating the average forecast of $4.6M by 531.34%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.18 by 94.44%